Results 21 to 30 of about 5,427 (131)
Therapeutic efficacy of nanomedicines for prostate cancer: An update [PDF]
Investigative and Clinical Urology, 2016 Recent advances in cancer nanomedicine have attracted remarkable attention in medical sectors. Pharmacologic research on nanomedicines, including targeted cancer therapy, has increased dramatically in the past 5 years.
Vinoth-Kumar Lakshmanan
doaj +1 more source
Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis
Frontiers in PharmacologyBackgroundAbraxane plays a crucial role in the treatment of various types of cancer, despite the considerable attention it has garnered for its adverse drug events (ADEs).
Yuanqiong Duan +13 more
doaj +1 more source
Tackling cancer stemness with nanotechnology in the era of precision medicine
BMEMat, EarlyView.Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo +9 more
wiley +1 more source
Dermatology Practical & Conceptual, 2015 Background: Taxanes [paclitaxel, nab-paclitaxel (Abraxane, Celgene Corp, USA), and docetaxel]—used in the treatment of lung, breast, and head and neck cancers—have been associated with cutaneous adverse effects, including photodermatoses.
Bryce D. Beutler, Philip R. Cohen
doaj +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma
Medicinal Research Reviews, EarlyView.ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo +4 more
wiley +1 more source
Plant‐Derived Natural Product Nanodelivery System in Cancer Therapy
Phytotherapy Research, EarlyView.This review comprehensively summarizes the recent progress and emerging concepts in nanotechnology‐based delivery systems for plant‐derived natural products, with a particular focus on their application in precision cancer therapy. ABSTRACT Plant‐derived natural products have emerged as important sources of anticancer agents because of their diverse ...
Changqi Shi +9 more
wiley +1 more source
Journal of Nanobiotechnology, 2021 In this article, we will describe the properties of albumin and its biological functions, types of sources that can be used to produce albumin nanoparticles, methods of producing albumin nanoparticles, its therapeutic applications and the importance of ...
Ehsan Kianfar
doaj +1 more source
ANZ Journal of Surgery, EarlyView.ABSTRACT Introduction Treatment sequencing is a major focus in pancreatic ductal adenocarcinoma (PDAC) treatment in recent literature. A neoadjuvant chemotherapy (NAC) first approach has been suggested to improve tumour stage and, in some cases, produce a total neoadjuvant response.
Emily R. Moran +3 more
wiley +1 more source
Case Reports in Oncological Medicine, 2023 Background. We describe a case report of a 67-year-old male with PDAC who experienced an exceptional survival outcome during systemic therapy and its implications in precision medicine.
Patsy W. P. Lee +2 more
doaj +1 more source